Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued on Sunday. The firm set a “hold” rating on the ...

Sorrento Therapeutics Inc. shareholders lack grounds to appeal a bankruptcy court’s decision blocking a broad probe into whether company attorneys sought to exploit a romantic relationship involving ...

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly ...

Investors in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) need to pay close attention to the stock based on moves in the options ...

Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01) The management of renal cell carcinoma (RCC) has seen significant ...

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any ...

CHICAGO, March 26, 2025 /PRNewswire/ -- The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.